MedTrace Logo

COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose

NCT05392075 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2026-03-24

No results posted yet for this study

Summary

A novel coronavirus, SARS-CoV-2 (formerly known as the 2019 novel coronavirus \[2019-nCoV\]) was identified as the agent that caused an outbreak of pneumonia (termed COVID-19) in Wuhan, China in December 2019. The virus quickly spread to other countries and on March 11, 2020, the World Health Organization (WHO) declared COVID-19 a pandemic. By March 2021, many nations and organizations embarked on finding a cure or vaccine for this devastating viral infection. The Pfizer COVID-19 mRNA vaccine was the first to obtain emergency use authorization (EUA) from the Food \& Drug Administration (FDA) on December 11, 2020, followed by the Moderna COVID-19 mRNA vaccine on December 18, 2020, and the Janssen COVID-19 viral vector vaccine on February 27, 2021. The mRNA vaccines and the viral vector vaccine are designed based on the spike protein of SARS-COV-2. These vaccines had been administered to millions of Americans prior to July 2021.

Conditions

Interventions

BIOLOGICAL

Pfizer COVID-19 mRNA vaccine

vaccinated people who received the Pfizer COVID-19 mRNA vaccine

BIOLOGICAL

Moderna COVID-19 mRNA vaccine

vaccinated people who received the Moderna COVID-19 mRNA vaccine vaccine

Sponsors & Collaborators

  • Methodist Health System

    lead OTHER

Principal Investigators

  • Valentine Ebuh, MD · Methodist Health System

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-15
Primary Completion
2023-03-15
Completion
2023-08-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05392075 on ClinicalTrials.gov